Dolasetron Mesylate (CAS 115956-13-3) Suppliers and Product Information

Dolasetron mesylate is an antiemetic drug, originally developed by Hoechst Marion Roussel. It is a selective serotonin 5-HT3 receptor antagonist, similar in action to ondansetron and granisetron. It is effective for preventing and treating nausea and vomiting caused by cancer chemotherapy and can also be used for postoperative nausea or vomiting prevention and treatment.

The drug is rapidly metabolized to hydrogenated dolasetron in plasma and liver. The active metabolite is further processed by CYP2D6 and CYP3A enzymes and excreted through urine and feces. The half-life of the product is approximately 8 hours.

Frequently Asked Questions about Dolasetron Mesylate

Q: What is the main use of Dolasetron mesylate?

A: Dolasetron mesylate is primarily used for preventing and treating nausea and vomiting caused by cancer chemotherapy. It can also be used for postoperative nausea and vomiting prevention and treatment.

Q: How does Dolasetron mesylate work?

A: Dolasetron mesylate works as a selective serotonin 5-HT3 receptor antagonist. It blocks 5-HT3 receptors in the central nervous system and vagal afferent fibers, resulting in a strong antiemetic effect.

Q: What are the common side effects of Dolasetron mesylate?

A: Common side effects include mild headache, dizziness, and transient ECG changes. These symptoms are usually not severe and often resolve on their own.

Q: Are there any precautions when using Dolasetron mesylate?

A: Yes, Dolasetron should not be used with drugs that affect heart function or prolong QT interval. It should be used with caution in patients with a history of heart disease or electrolyte imbalances. Pregnant and lactating women should also use it cautiously.